Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 2/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317690 | 0.79 | SMN1; SMN2 (0.35) | EPAS1KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL2961511 | 0.70 | HTR7 (0.43) | EPAS1KDM4EALDH1A1MAPT | |
| SCHEMBL2961014 | 0.69 | GABRP (0.39) | KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL317502 | 0.67 | MEN1 (0.42) | KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL3980764 | 0.66 | CYP1A2 (0.46) | KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL2959702 | 0.65 | KIF11 (0.48) | KDM4E | |
| SCHEMBL28563540 | 0.62 | MAPT (0.60) | EPAS1KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL30987223 | 0.62 | MAPT (0.60) | EPAS1KDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL3234433 | 0.60 | KRAS (0.52) | HSD17B10 | |
| SCHEMBL6246287 | 0.60 | KDM4E (0.33) | EPAS1KDM4EALDH1A1MAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093278-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20100210685-A1 | Novel Substituted Indoles | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7754735-B2 | Substituted indoles | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1549634-A1 | NOVEL SUBSTITUTED INDOLES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003101981-A1 | NOVEL SUBSTITUTED INDOLES | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210685-A1 | Novel Substituted Indoles | IDO1, IDO2, TPH1 | EPAS1 416/4885PDE7A 3634/4885KDM4E 1758/4885 |
| US-20050222201-A1 | such as 3-(2-chloro-4-quinolinyl)-2,5-dimethyl-1H-indole-1-acetic acid, used for treating respiratory system disorders and as inhibitors of G protein-coupled receptor chemoattractant homologous receptor expressed on lymphocyte cells (CRTH2) | HRH2, HRH1, HCAR2 | EPAS1 1248/4885PDE7A 672/4885KDM4E 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.